Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated:  12/31/1969
MetroHealth CRS
mi
from
Cleveland, OH
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated: 12/31/1969
MetroHealth CRS
mi
from
Cleveland, OH
Click here to add this to my saved trials
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated:  12/31/1969
Penn Therapeutics Crs
mi
from
Philadelphia, PA
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated: 12/31/1969
Penn Therapeutics Crs
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated:  12/31/1969
The Miriam Hospital Clinical Research Site (TMH CRS) CRS
mi
from
Providence, RI
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated: 12/31/1969
The Miriam Hospital Clinical Research Site (TMH CRS) CRS
mi
from
Providence, RI
Click here to add this to my saved trials
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth Univ. Medical Ctr. CRS
mi
from
Richmond, VA
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth Univ. Medical Ctr. CRS
mi
from
Richmond, VA
Click here to add this to my saved trials
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated:  12/31/1969
Puerto Rico AIDS Clinical Trials Unit CRS
mi
from
San Juan,
Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection
Status: Enrolling
Updated: 12/31/1969
Puerto Rico AIDS Clinical Trials Unit CRS
mi
from
San Juan,
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
31788 Alabama CRS
mi
from
Birmingham, AL
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
31788 Alabama CRS
mi
from
Birmingham, AL
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
UCLA CARE Center CRS (601)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
701 University of California, San Diego AntiViral Research Center CRS
mi
from
San Diego, CA
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
701 University of California, San Diego AntiViral Research Center CRS
mi
from
San Diego, CA
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
801 University of California, San Francisco HIV/AIDS CRS
mi
from
San Francisco, CA
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
801 University of California, San Francisco HIV/AIDS CRS
mi
from
San Francisco, CA
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
University of Colorado Hospital CRS (6101)
mi
from
Aurora, CO
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Northwestern University CRS (2701)
mi
from
Chicago, IL
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Rush University Medical Center (2702)
mi
from
Chicago, IL
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Rush University Medical Center (2702)
mi
from
Chicago, IL
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Adult AIDS CRS (201)
mi
from
Baltimore, MD
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Adult AIDS CRS (201)
mi
from
Baltimore, MD
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
31786 New Jersey Medical School Clinical Research Center CRS
mi
from
Newark, NJ
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
31786 New Jersey Medical School Clinical Research Center CRS
mi
from
Newark, NJ
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
7804 Weill Cornell Chelsea CRS
mi
from
New York, NY
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
7804 Weill Cornell Chelsea CRS
mi
from
New York, NY
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Columbia Physicians and Surgeons CRS (30329)
mi
from
New York, NY
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Columbia Physicians and Surgeons CRS (30329)
mi
from
New York, NY
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
7803 Weill Cornell Upton CRS
mi
from
New York, NY
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
7803 Weill Cornell Upton CRS
mi
from
New York, NY
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Unc Aids Crs
mi
from
Chapel Hill, NC
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Unc Aids Crs
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Greensboro CRS (3203)
mi
from
Greensboro, NC
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Greensboro CRS (3203)
mi
from
Greensboro, NC
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Univ. of Cincinnati CRS (2401)
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Case CRS (2501)
mi
from
Cleveland, OH
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Case CRS (2501)
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
6201 Penn Therapeutics CRS
mi
from
Philadelphia, PA
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
6201 Penn Therapeutics CRS
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Pittsburgh CRS (1001)
mi
from
Pittsburgh, PA
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Pittsburgh CRS (1001)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Vanderbilt Therapeutics CRS (3652)
mi
from
Nashville, TN
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Trinity Health and Wellness Center CRS (31443)
mi
from
Dallas, TX
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Trinity Health and Wellness Center CRS (31443)
mi
from
Dallas, TX
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Houston AIDS Research Team CRS (31473)
mi
from
Houston, TX
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
University of Washington AIDS CRS (1401)
mi
from
Seattle, WA
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
University of Washington AIDS CRS (1401)
mi
from
Seattle, WA
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Puerto Rico-AIDS CRS (5401)
mi
from
San Juan,
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Puerto Rico-AIDS CRS (5401)
mi
from
San Juan,
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
Washington University CRS (2101)
mi
from
Saint Louis, MO
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
Washington University CRS (2101)
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated:  12/31/1969
The Ohio State Univ. AIDS CRS (2301)
mi
from
Columbus, OH
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers
Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study
Status: Enrolling
Updated: 12/31/1969
The Ohio State Univ. AIDS CRS (2301)
mi
from
Columbus, OH
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Phoenix, AZ
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Orlando, FL
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Decatur, GA
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Decatur, GA
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Saint Louis, MO
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Fort Pierce, FL
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Fort Pierce, FL
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Berkley, MI
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Berkley, MI
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
West Palm Beach, FL
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Indianapolis, IN
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Indianapolis, IN
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Springfield, MA
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Springfield, MA
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Chapel Hill, NC
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Allentown, PA
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Allentown, PA
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Providence, RI
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Providence, RI
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Ciudad Autonoma de Buenos Aires,
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Kansas City, MO
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Kansas City, MO
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Bellaire, TX
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Bellaire, TX
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Washington,
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)
A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Dallas, TX
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
San Francisco, CA
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Hillsborough, NJ
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Hillsborough, NJ
Click here to add this to my saved trials
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Birmingham, AL
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)
A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials